Cargando…

Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse

PURPOSE: Acute promyelocytic leukemia (APL) is the most prognostically favorable subtype of Acute myeloid leukemia (AML). Defining the features that allow identification of APL patients likely to relapse after therapy remains challenging. EXPERIMENTAL DESIGN: Proteomic profiling is performed on 20 n...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoff, Fieke W., Hu, Chenyue W., Qutub, Amina A., Qiu, Yihua, Hornbaker, Marisa J., Bueso‐Ramos, Carlos, Abbas, Hussein A., Post, Sean M., de Bont, Eveline S. J. M., Kornblau, Steven M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635093/
https://www.ncbi.nlm.nih.gov/pubmed/30650251
http://dx.doi.org/10.1002/prca.201800133
_version_ 1783435813504155648
author Hoff, Fieke W.
Hu, Chenyue W.
Qutub, Amina A.
Qiu, Yihua
Hornbaker, Marisa J.
Bueso‐Ramos, Carlos
Abbas, Hussein A.
Post, Sean M.
de Bont, Eveline S. J. M.
Kornblau, Steven M.
author_facet Hoff, Fieke W.
Hu, Chenyue W.
Qutub, Amina A.
Qiu, Yihua
Hornbaker, Marisa J.
Bueso‐Ramos, Carlos
Abbas, Hussein A.
Post, Sean M.
de Bont, Eveline S. J. M.
Kornblau, Steven M.
author_sort Hoff, Fieke W.
collection PubMed
description PURPOSE: Acute promyelocytic leukemia (APL) is the most prognostically favorable subtype of Acute myeloid leukemia (AML). Defining the features that allow identification of APL patients likely to relapse after therapy remains challenging. EXPERIMENTAL DESIGN: Proteomic profiling is performed on 20 newly diagnosed APL, 205 non‐APL AML, and 10 normal CD34+ samples using Reverse Phase Protein Arrays probed with 230 antibodies. RESULTS: Comparison between APL and non‐APL AML samples identifies 8.3% of the proteins to be differentially expressed. Proteins higher expressed in APL are involved in the pro‐apoptotic pathways or are linked to higher proliferation. The “MetaGalaxy” approach that considers proteins in relation to other assayed proteins stratifies the APL patients into two protein signatures. All of the relapse patients (n = 4/4) are in protein signature 2 (S2). Comparison of proteins between the signatures shows significant differences in relative expression for 38 proteins. Protein expression summary plots suggest less translational activity in combination with a less proliferative character for S2 compared to signature 1. CONCLUSIONS AND CLINICAL RELEVANCE: This study provides a potential proteomic‐based classification of APL patients that may be useful for risk stratification and therapeutic guidance. Validation in a larger independent cohort is required.
format Online
Article
Text
id pubmed-6635093
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-66350932019-10-03 Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse Hoff, Fieke W. Hu, Chenyue W. Qutub, Amina A. Qiu, Yihua Hornbaker, Marisa J. Bueso‐Ramos, Carlos Abbas, Hussein A. Post, Sean M. de Bont, Eveline S. J. M. Kornblau, Steven M. Proteomics Clin Appl Research Articles PURPOSE: Acute promyelocytic leukemia (APL) is the most prognostically favorable subtype of Acute myeloid leukemia (AML). Defining the features that allow identification of APL patients likely to relapse after therapy remains challenging. EXPERIMENTAL DESIGN: Proteomic profiling is performed on 20 newly diagnosed APL, 205 non‐APL AML, and 10 normal CD34+ samples using Reverse Phase Protein Arrays probed with 230 antibodies. RESULTS: Comparison between APL and non‐APL AML samples identifies 8.3% of the proteins to be differentially expressed. Proteins higher expressed in APL are involved in the pro‐apoptotic pathways or are linked to higher proliferation. The “MetaGalaxy” approach that considers proteins in relation to other assayed proteins stratifies the APL patients into two protein signatures. All of the relapse patients (n = 4/4) are in protein signature 2 (S2). Comparison of proteins between the signatures shows significant differences in relative expression for 38 proteins. Protein expression summary plots suggest less translational activity in combination with a less proliferative character for S2 compared to signature 1. CONCLUSIONS AND CLINICAL RELEVANCE: This study provides a potential proteomic‐based classification of APL patients that may be useful for risk stratification and therapeutic guidance. Validation in a larger independent cohort is required. John Wiley and Sons Inc. 2019-02-04 2019-07 /pmc/articles/PMC6635093/ /pubmed/30650251 http://dx.doi.org/10.1002/prca.201800133 Text en © 2019 The Authors. Proteomics – Clinical Application published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Hoff, Fieke W.
Hu, Chenyue W.
Qutub, Amina A.
Qiu, Yihua
Hornbaker, Marisa J.
Bueso‐Ramos, Carlos
Abbas, Hussein A.
Post, Sean M.
de Bont, Eveline S. J. M.
Kornblau, Steven M.
Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse
title Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse
title_full Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse
title_fullStr Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse
title_full_unstemmed Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse
title_short Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse
title_sort proteomic profiling of acute promyelocytic leukemia identifies two protein signatures associated with relapse
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635093/
https://www.ncbi.nlm.nih.gov/pubmed/30650251
http://dx.doi.org/10.1002/prca.201800133
work_keys_str_mv AT hofffiekew proteomicprofilingofacutepromyelocyticleukemiaidentifiestwoproteinsignaturesassociatedwithrelapse
AT huchenyuew proteomicprofilingofacutepromyelocyticleukemiaidentifiestwoproteinsignaturesassociatedwithrelapse
AT qutubaminaa proteomicprofilingofacutepromyelocyticleukemiaidentifiestwoproteinsignaturesassociatedwithrelapse
AT qiuyihua proteomicprofilingofacutepromyelocyticleukemiaidentifiestwoproteinsignaturesassociatedwithrelapse
AT hornbakermarisaj proteomicprofilingofacutepromyelocyticleukemiaidentifiestwoproteinsignaturesassociatedwithrelapse
AT buesoramoscarlos proteomicprofilingofacutepromyelocyticleukemiaidentifiestwoproteinsignaturesassociatedwithrelapse
AT abbashusseina proteomicprofilingofacutepromyelocyticleukemiaidentifiestwoproteinsignaturesassociatedwithrelapse
AT postseanm proteomicprofilingofacutepromyelocyticleukemiaidentifiestwoproteinsignaturesassociatedwithrelapse
AT debontevelinesjm proteomicprofilingofacutepromyelocyticleukemiaidentifiestwoproteinsignaturesassociatedwithrelapse
AT kornblaustevenm proteomicprofilingofacutepromyelocyticleukemiaidentifiestwoproteinsignaturesassociatedwithrelapse